Autologous TriMix-DC Therapeutic Vaccine in Combination With Ipilimumab in Patients With Previously Treated Unresectable Stage III or IV Melanoma

NCT01302496 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Malignant Melanoma Stage III
Malignant Melanoma Stage IV

Interventions

BIOLOGICAL: TriMix-DC and ipilimumab

Sponsor

Bart Neyns

Collaborators

[object Object]